Company news

BioCryst Pharmaceuticals, Inc. news in 2025

BioCryst Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years

December 11, 2025

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

December 2, 2025

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

November 12, 2025

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

November 5, 2025

BioCryst to Present at Upcoming Investor Conference

November 4, 2025

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

November 2, 2025

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

October 22, 2025

BioCryst to Report Third Quarter 2025 Financial Results on November 3

October 19, 2025

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

October 13, 2025

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

September 30, 2025

BioCryst Announces Departure of Dr. Helen Thackray

August 10, 2025

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

August 3, 2025

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

July 30, 2025

BioCryst to Report Second Quarter 2025 Financial Results on August 4

July 20, 2025

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

July 8, 2025

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

July 6, 2025

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

June 26, 2025

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

June 15, 2025

ORLADEYO® (berotralstat) Approved in Colombia

June 12, 2025

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

June 5, 2025

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

June 1, 2025

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 29, 2025

BioCryst to Present at Upcoming Investor Conferences

May 26, 2025

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 15, 2025

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 13, 2025

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025

BioCryst Appoints Steve Frank to Board of Directors

April 30, 2025

BioCryst to Report First Quarter 2025 Financial Results on May 5

April 20, 2025

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

February 23, 2025

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

February 23, 2025

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

February 11, 2025

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

February 9, 2025

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

February 9, 2025

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

January 9, 2025

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Calls in 2025

Decks in 2025